What 6 Analyst Ratings Have To Say About Zymeworks
Portfolio Pulse from Benzinga Insights
In the last quarter, 6 analysts provided ratings for Zymeworks (NASDAQ:ZYME), with 3 being bullish, 1 somewhat bullish, and 2 indifferent. The average 12-month price target is $13.67, a 4.61% decrease from the previous average of $14.33.
May 18, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zymeworks (NASDAQ:ZYME) received mixed ratings from 6 analysts in the last quarter, with an average 12-month price target of $13.67, down 4.61% from the previous average.
The mixed ratings from analysts indicate uncertainty about Zymeworks' stock performance in the short term. The average 12-month price target has decreased by 4.61%, suggesting a potential decline in the stock price. However, the ratings are not overwhelmingly negative, so the short-term impact is neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100